Skip to main content
Top
Published in: Hepatology International 2/2023

13-10-2022 | Nutrition | Original Article

Association of age at first birth and risk of non-alcoholic fatty liver disease in women: evidence from the NHANES

Authors: Huan-Huan Yang, Guo-Chong Chen, Meng-Ge Zhou, Li-Feng Xie, Yuan-Yuan Jin, Hao-Tian Chen, Ze-Kun Chen, Yu-Hao Kong, Chang-Zheng Yuan, Zhi-Hui Li

Published in: Hepatology International | Issue 2/2023

Login to get access

Abstract

Background

Numerous studies have suggested that age at first birth (AFB) is inversely associated with metabolic diseases, but positively associated with liver cancer in women. Non-alcoholic fatty liver disease (NAFLD) is a canonical example of metabolic dysfunction and inflammation-based liver disease, while the association between AFB and the risk of NAFLD remains unclear. We aimed to investigate the association between AFB and the odds of NAFLD in women.

Methods

Women older than 20 years at the time of the survey were analyzed using National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2018 in the US. AFB was obtained with self-administered questionnaires. NAFLD was diagnosed as fatty liver index (FLI) ≥ 60. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression models.

Results

Of the 12,188 women included in this study, 5670 (46.5%) had NAFLD. Compared to individuals with AFB of 30–32 years old (reference group), the fully adjusted ORs and 95% CI in women with AFB < 18, 18–20, 21–23, and 24–26 years were 1.52 (95% CI 1.14, 2.03), 1.60 (95% CI 1.21, 2.11), 1.40 (95% CI 1.06, 1.84), and 1.33 (95% CI 1.01–1.76), respectively. Yet there was no significant difference between AFB of 27–29, 33–35, or > 35 years compared to the reference group.

Conclusions

Women with younger AFB have higher odds of NAFLD in later life. Policymakers should consider focusing on those with earlier AFB for screening and prevention of NAFLD.
Appendix
Available only for authorised users
Literature
Metadata
Title
Association of age at first birth and risk of non-alcoholic fatty liver disease in women: evidence from the NHANES
Authors
Huan-Huan Yang
Guo-Chong Chen
Meng-Ge Zhou
Li-Feng Xie
Yuan-Yuan Jin
Hao-Tian Chen
Ze-Kun Chen
Yu-Hao Kong
Chang-Zheng Yuan
Zhi-Hui Li
Publication date
13-10-2022
Publisher
Springer India
Published in
Hepatology International / Issue 2/2023
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10429-1

Other articles of this Issue 2/2023

Hepatology International 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine